Industry news that matters to you.  Learn more

Archives for December 2010

Biomarker Finding Opens New Front in War on Cancer

Two researchers from Toronto’s Mount Sinai Hospital have discovered a potential key common biomarker in at least 10 different aggressive cancers, a medical breakthrough they say can lead to early diagnosis and better treatment.

The findings were published Tuesday in the peer-reviewed Public Library of Science One journal.

BG Medicine Announces FDA Clearance of its Galectin-3 Test for Use in Patients with Chronic HF

BG Medicine, Inc., a U.S.-based life sciences company, announced today that the U.S. Food and Drug Administration has cleared the company’s Galectin-3 test for use in conjunction with clinical evaluation as an aid to assess the prognosis of patients diagnosed with chronic heart failure. This marks the first time the FDA has cleared a test to measure galectin-3 blood levels, and is the first novel cardiac test cleared by the FDA in five years.

OSI Pays Aveo $25M for Rights to Use Human Response Platform

The Astellas subsidiary OSI Pharmaceuticals will pay Aveo Pharmaceuticals $25 million to exercise its option to take on specific elements of the latter’s Human Response platform (HRP) technology in support of its own clinical development programs. The transferred technology will include components of the HRP platform for identifying and characterizing novel epithelial-mesenchymal transition (EMT) agents and patient-selection biomarkers.